This Article Full Text Full Text (PDF) All Versions of this Article: clinchem.2009.133272v1 56/1/34    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Li, H. Articles by Ma, J. Search for Related Content PubMed PubMed Citation Articles by Li, H. Articles by Ma, J. Related Collections Endocrinology and Metabolism

A 25-Year Prospective Study of Plasma Adiponectin and Leptin Concentrations and Prostate Cancer Risk and Survival

¹ GlaxoSmithKline R&D, Worldwide Epidemiology (Oncology), Collegeville, PA; ² Channing Laboratory, Department of Medicine, Brigham and Women’s Hospital, Boston, MA; ³ Harvard Medical School, Boston, MA; Departments of ⁴ Epidemiology and ⁵ Nutrition, Harvard School of Public Health, Boston, MA; ⁶ Department of Laboratory Medicine, Children’s Hospital, Harvard Medical School, Boston, MA; ⁷ Division of Preventive Medicine, Department of Medicine, Brigham and Women’s Hospital, Boston, MA.

^aAddress correspondence to this author at: 181 Longwood Avenue, Boston, MA 02115. Fax 617–525-2008; e-mail jing.ma{at}channing.harvard.edu.

Background: Adipocytokines may mediate the association between adiposity and lethal prostate cancer outcomes.

Methods: In the Physicians’ Health Study, we prospectively examined the association of prediagnostic plasma concentrations of adiponectin and leptin with risk of developing incident prostate cancer (654 cases diagnosed 1982–2000 and 644 age-matched controls) and, among cases, risk of dying from prostate cancer by 2007.

Results: Adiponectin concentrations were not associated with risk of overall prostate cancer. However, men with higher adiponectin concentrations had lower risk of developing high-grade or lethal cancer (metastatic or fatal disease). The relative risk (95% CI) comparing the highest quintile to the lowest (Q5 vs Q1) was 0.25 (95% CI 0.07–0.87; P_trend = 0.02) for lethal cancer. Among all the cases, higher adiponectin concentrations predicted lower prostate cancer–specific mortality [hazard ratio (HR)_{Q5 vs Q1}= 0.39; 95% CI 0.17–0.85; P_trend = 0.02], independent of body mass index (BMI), plasma C-peptide (a marker of insulin secretion), leptin, clinical stage, and tumor grade. This inverse association was apparent mainly among men with a BMI 25 kg/m² (HR_{Q5 vs Q1}= 0.10; 95% CI 0.01–0.78; P_trend = 0.02), but not among men of normal weight (P_trend = 0.51). Although the correlation of leptin concentrations with BMI (r = 0.58, P < 0.001) was stronger than that of adiponectin (r = –0.17, P < 0.001), leptin was unrelated to prostate cancer risk or mortality.

Conclusions: Higher prediagnostic adiponectin (but not leptin) concentrations predispose men to a lower risk of developing high-grade prostate cancer and a lower risk of subsequently dying from the cancer, suggesting a mechanistic link between obesity and poor prostate cancer outcome.

The following articles in journals at HighWire Press have cited this article:

				G. Zadra, C. Priolo, A. Patnaik, and M. Loda New Strategies in Prostate Cancer: Targeting Lipogenic Pathways and the Energy Sensor AMPK Clin. Cancer Res., July 1, 2010; 16(13): 3322 - 3328. [Abstract] [Full Text] [PDF]

				S. J. Freedland, C. D. Williams, and E. M. Masko Adiponectin and Prostate Cancer Mortality: To Be or Not to Be Skinny? Clin. Chem., January 1, 2010; 56(1): 1 - 3. [Full Text] [PDF]